BofA analyst Travis Steed lowered the firm’s price target on Insulet to $180 from $295 and keeps a Buy rating on the shares. While the firm contends that current medtech multiples have “likely discounted too much for GLP-1 concerns,” unless expectations change on GLP-1 weight-loss drugs, medtech likely will trade at some discount compared to recent history and the firm lowering some targets in the group to reflect this new discount as well as higher interest rates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PODD:
- Early notable gainers among liquid option names on October 18th
- Insulet price target lowered to $162 from $325 at JPMorgan
- Wayfair upgraded, JD.com downgraded: Wall Street’s top analyst calls
- Insulet initiated with an Outperform at Leerink
- Wells sees preliminary injunction in Insulet case against EOFlow